Patents Assigned to Jiangsu Hengrui Medicine Co., Ltd.
  • Publication number: 20210040171
    Abstract: A composition comprising a human insulin analog. In particular, provided is a composition comprising an acylated derivative of a human insulin analog. The acylated derivative composition is more stable than an existing insulin analog and an acylated derivative composition thereof.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 11, 2021
    Applicant: JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventor: Xiaorong YANG
  • Patent number: 10906905
    Abstract: The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring bridged ring derivative as shown in formula (I), a preparation method therefor and a pharmaceutical composition comprising the derivative, and the use thereof as a therapeutic agent, in particular as a TGF-? inhibitor, and the use in the preparation of a drug for treating, preventing or reducing cancers mediated by the over-expression of TGF-?, wherein the definition of each substituent in the general formula (I) is the same as defined in the description.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: February 2, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Shanghai Yu, Fanglong Yang, Jingjing Yan, Xiao Wu, Feng He, Weikang Tao
  • Patent number: 10899741
    Abstract: The present invention relates to a 3,4-bipyridyl pyrazole derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a new 3,4-bipyridyl pyrazole derivative as shown in formula (I), a preparation method for the derivative, a pharmaceutical composition containing the derivative, a use of the derivative as a therapeutic agent, in particular as a TGF-? inhibitor, and a use of the derivative in the preparation of a drug which treats, prevents or reduces cancer mediated by TGF-? overexpression. The substituents in formula (I) have the same definitions as in the description.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: January 26, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Guangyuan Shen, Feng He, Weikang Tao
  • Patent number: 10899837
    Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: January 26, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jinming Gu, Xiaohua Wang, Xin Ye, Liuqing Yang, Ting Zhang, Weikang Tao, Lianshan Zhang
  • Patent number: 10899764
    Abstract: The present invention relates to an imidazo isoindole derivative, a preparation method therefor and a medical use thereof. In particular, the present invention relates to the imidazo isoindole derivative as shown in the formula (I), a preparation method and pharmaceutical composition containing the derivative, and a use thereof for treating diseases with a pathological characteristic of the IDO-mediated tryptophan metabolic pathways. The diseases comprise cancers, Alzheimer's disease, autoimmune diseases, depression, anxiety disorders, cataracts, psychological disorders and AIDS, wherein the substituents in the formula (I) are the same as those defined in the specification.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: January 26, 2021
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHRMACEUTICAL CO., LTD.
    Inventors: Wangyang Tu, Guoji Xu, Haitang Zhang, Jiangtao Chi, Qing Dong
  • Patent number: 10889569
    Abstract: A condensed ring group azacyclobutyl triazole derivative, a preparation method therefor and use thereof in medicine are provided. In particular, a condensed ring group azacyclobutyl triazole derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, use thereof as a therapeutic agent, in particular as an oxytocin antagonist, and for treating or preventing a disease or a condition that is known or can exhibit a beneficial effect of inhibiting oxytocin are provided. The definition for each substituent in general formula (I) is the same as that in the description.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 12, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Wei He, Bin Wang, Zhigao Zhang, Feng He, Weikang Tao
  • Patent number: 10889546
    Abstract: The present invention relates to the field of pharmaceutical chemistry. In particular, the present invention relates to a class of alkynyl pyridine prolyl hydroxylase inhibitors (I). The experiments show that such a compound has good activity of inhibiting prolyl hydroxylase, and can enhance the generation and secretion of erythropoietin in cell or animal models, and thus can promote the generation of red cells, and can be used for the treatment or prevention of anemia, such as chronic kidney disease anemia, and ischemic diseases, including ischemic strokes, myocardial ischemia and other related diseases. The present invention also discloses a method for preparing such a compound.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: January 12, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Qidong You, Xiaojin Zhang, Yonghua Lei, Tianhan Hu, Xingsen Wu, Haopeng Sun, Xiaoke Guo, Xiaoli Xu
  • Patent number: 10857146
    Abstract: A method for preventing or treating tumor diseases with a combination of a tyrosine kinase inhibitor and a CDK4/6 inhibitor is provided. In particular, a method for preventing or treating tumor diseases, including administering to a patient a tyrosine kinase inhibitor of a compound of formula (I), or a complex, a pharmaceutically acceptable salt or a stereoisomer thereof and a CDK4/6 inhibitor is provided.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: December 8, 2020
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Jiahua Jiang, Cheng Liao, Lianshan Zhang, Piaoyang Sun, Lin Shen, Jing Gao, Jifang Gong
  • Patent number: 10851100
    Abstract: Disclosed are an intermediate of a pyrrolo six-membered heteroaromatic ring derivative as a JAK inhibitor and a preparation method therefor, and a method for preparing a pyrrolo six-membered heteroaromatic ring derivative using the intermediate. The method improves the reaction yield, is simple and easy to operate and control, and is conducive to expanded industrial production.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 1, 2020
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Bing Liu, Lin Bian, Xiaohui Gao
  • Publication number: 20200369774
    Abstract: Provided in the present invention are an IL-6R antibody and antigen-binding fragment thereof. The IL-6R antibody is an alpaca-derived antibody, chimeric antibody and humanized antibody. Also provided in the present invention is the use of the antibody in the preparation of a drug for treating IL-6-related diseases.
    Type: Application
    Filed: September 12, 2018
    Publication date: November 26, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Hua Ying, Houcong Jin, Qiyue Hu, Hu Ge, Yifang Wang, Weikang Tao
  • Publication number: 20200339692
    Abstract: A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.
    Type: Application
    Filed: January 9, 2019
    Publication date: October 29, 2020
    Applicants: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xiaoling GU, Jiahua JIANG, Lei ZHANG, Qiyue HU, Jinming GU, Weikang TAO
  • Patent number: 10815304
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 27, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • Patent number: 10815287
    Abstract: Provided is an acylated derivative of human insulin or an analogue thereof. Specifically disclosed is an acylated derivative of a human insulin analogue, or zinc complex thereof; the human insulin analogue being derivatized is preferably Des(B30) human insulin; the acylated derivative is longer-lasting than existing insulin analogues and acylated derivatives thereof, its blood glucose reduction is more steady, and it is more stable in storage.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 27, 2020
    Assignee: JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Deyu Liu, Hongwei Wang, Liang Zhao, Feifei Wang, Xiang Zeng, Tao Wang, Yali Wang, Yulu Dai
  • Patent number: 10793643
    Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 6, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Xin Ye, Shaoyu Xu, Bei Yuan, Dongbing Cui, Qiyue Hu, Lei Zhang, Zhibin Xu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Patent number: 10793548
    Abstract: The present invention relates to a method for preparing a tyrosine kinase inhibitor and a derivative thereof. The present method has a short synthesis route, low costs, easy operation, and is suitable for large-scale production.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: October 6, 2020
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Guaili Wu, Quanliang Zhang, Yongxing Cao
  • Patent number: 10786507
    Abstract: Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 29, 2020
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Hao Chen, Xiaochen Pan
  • Patent number: 10787451
    Abstract: Provided are a crystalline form of a GnRH receptor antagonist and a preparation method therefor. Specifically, provided are a crystalline form I of 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl)-5-(6-methoxypyridazin-3-yl)-4,6-dicarbonyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)phenyl)-3-methoxy urea (a compound of formula I) and a preparation method, the use of same in a pharmaceutical composition and the use of the crystalline form I and the composition in the preparation of a drug for treating diseases associated with a GnRH receptor antagonist.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 29, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Suncadia Pharmaceuticals Co., Ltd.
    Inventors: Quanliang Zhang, Junlei Jia, Lin Bian, Xiaohui Gao
  • Publication number: 20200277278
    Abstract: A deuterium atom-substituted indole formamide derivative, a preparation method therefor, and medical applications thereof. Specifically, the present invention relates to a deuterium atom-substituted indole formamide derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and uses of the derivative serving as an ROR agonist and uses of the derivative in preventing and/or treating tumors or cancers, definitions of substituent groups in general formula (I) being same as definitions in the specification.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Dong Liu, Lei Chen, Biao Lu, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Patent number: 10759788
    Abstract: Pharmaceutical uses of pyridinecarboxamide derivatives are provided. In particular, pharmaceutical uses of pyridinecarboxamide derivatives represented by general formula (I), wherein the substituents of the formula (I) are defined in the specification, are provided. The pyridinecarboxamide derivatives can be used as therapeutic agents, especially as inhibitors of the Renal Outer Medullary Potassium channel (ROMK) and in the preparation of medicaments for treating and/or preventing ROMK mediated disorders, such as hypertension and heart failure.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 1, 2020
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xin Li, Qing Dong, Piaoyang Sun
  • Patent number: 10759787
    Abstract: The present invention relates to a benzofuran derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to the benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, wherein the definitions of the substituents in the general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: September 1, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Biao Lu, Xiaodong Shen, Mingxun He, Dong Liu, Minsheng Zhang